Indicated to address retroviral duplication to manage HIV disease and alleviate risk of viral progression.
Mechanism of Action
Combines three active agents to block retroviral integration and reverse transcription, halting viral chain growth.
Route of Administration
Oral
Onset Time
2–4 weeks
Duration
24 hours
Contraindications
Severe renal impairment, Concurrent dofetilide use, Severe hepatic failure
Severe Adverse Events
Lactic acidosis — requires immediate medical attention, Hepatotoxicity — requires immediate medical attention, Severe acute hepatitis B flare — requires immediate medical attention
Common Side Effects
Headache, Nausea, Insomnia
Uncommon Side Effects
Diarrhea, Fatigue, Elevated cholesterol
Drug Interactions
Antacids, Rifampin, Carbamazepine
Pregnancy Safety Warnings
TGA Category B/C: Use if benefit outweighs risk. Avoid in early pregnancy. Breastfeeding: Not recommended.
Age Restrictions
Approved for adults weighing over forty kilograms.
Information related to Viropil is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
